Genmab AS reported net sales figures for its cancer treatment DARZALEX® in Q3 2026.
Genmab AS announced net sales of its multiple myeloma treatment, DARZALEX® (daratumumab), for the third quarter of 2026. This report highlights the ongoing demand for the drug as cancer treatment expenditures continue to rise, projected to exceed $400 billion. The stock closed at US$38.25, up 0.88% for the day, with a year-to-date gain of 15.93%.
Investor takeaway: Investors should monitor how DARZALEX® sales impact Genmab's overall financial performance going forward.
Advertisement
Genmab AS
GMAB.US
GMAB.US
Genmab AS
WealthAwesomeMarket cap
$22.68B
P/E
29.0x
52W high
$40.17
52W low
$23.62
1W change
+0.65%
Beta
0.65
Analyst Price Targets
Based on 12 analysts covering GMAB · as of Oct 14, 2026
Wall Street analysts forecast GMAB stock price to rise 20.4% over the next 12 months.
Consensus
Strong Buy4.75 / 5.00
Avg. Target
C$44.40
+20.4% Upside
Previously C$44.13 on Oct 12, 2026
Current Price
C$36.89
Last close
Analyst Breakdown (12 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GMAB's historical volatility
30-Day Vol
40.7%
Annualized
90-Day Vol
33.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$44.10
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$39.15 | C$34.02 – C$45.06 |
| 60 trading days | C$41.55 | C$34.06 – C$50.69 |
| 90 trading days | C$44.10 | C$34.57 – C$56.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Latest Sales Figures for DARZALEX®
Genmab's latest sales report reflects the growing importance of its cancer treatments in a competitive market.
Bull case
The strong sales figures for DARZALEX® suggest robust demand, which could drive future revenue growth for Genmab.
Bear case
If sales growth falls short of market expectations, it may raise concerns about the company's ability to maintain its current valuation.
Genmab Reports Q3 Sales for DARZALEX®
Advertisement
Genmab AS has released its net sales figures for DARZALEX® (daratumumab) for the third quarter of 2026. While specific sales figures were not disclosed, the context of increasing cancer treatment investments indicates that Genmab is well-positioned to benefit from this trend. The stock's last close was US$38.25, reflecting a 0.88% increase on the day, while the company has seen a 1-month gain of 12.99% and a year-to-date rise of 15.93%.
Sales Performance in Context
The trading volume for Genmab on the day of the announcement was 1,811,142 shares, which is 0.66 times the 20-day average volume of 4,056,110 shares. The stock is currently trading above both its 50-day moving average of US$33.84 and its 200-day moving average of US$29.79, indicating positive momentum. Additionally, Genmab's P/E ratio stands at 29.05, suggesting a premium valuation in the market.
What to Watch Next for Genmab
Investors should keep an eye on future sales reports for DARZALEX® and how they align with market expectations. The stock's 52-week range of US$23.62 to US$40.17 indicates substantial volatility, with the current price being near the upper end of this range. Furthermore, the average analyst target for Genmab is US$44.40, implying a potential upside of 16.1%, which could guide investor sentiment in the coming weeks.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
